@article{84d4e0ccc26149ad8919c01882d373fc,
title = "The Evolving Role of Neurosurgical Intervention for Central Nervous System Tumors",
keywords = "Brain tumors, Gliomas, Innovation, Multidisciplinary approach, Neurosurgery",
author = "Pierpaolo Peruzzi and Valdes, \{Pablo Q.\} and Aghi, \{Manish K.\} and Mitchel Berger and Chiocca, \{Ennio Antonio\} and Golby, \{Alexandra J.\}",
note = "Funding Information: P. Peruzzi has received research support from NIH , Neurosurgery Research and Education Foundation , and The Sontag Foundation . He is named inventor on patents related to noncoding RNA technology. E.A. Chiocca is currently an advisor to Advantagene Inc., Alcyone Biosciences, Insightec, Inc., DNAtrix Inc, Immunomic Therapeutics, Seneca Therapeutics, GSK, and Voyager Therapeutics and has equity interest in DNAtrix, Immunomic Therapeutics, and Seneca Therapeutics; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx., Ziopharm Oncology, Cerebral Therapeutics, Genenta. Merck, Janssen, Karcinolysis, Shanghai Biotech, and Sangamo Therapeutics. He has received research support from NIH, US Department of Defense , American Brain Tumor Association , National Brain Tumor Society , Alliance for Cancer Gene Therapy , Neurosurgical Research Education Foundation, Advantagene , NewLink Genetics , and Amgen . He also is a named inventor on patents related to oncolytic HSV1 and noncoding RNAs. Funding Information: P. Peruzzi has received research support from NIH, Neurosurgery Research and Education Foundation, and The Sontag Foundation. He is named inventor on patents related to noncoding RNA technology. E.A. Chiocca is currently an advisor to Advantagene Inc. Alcyone Biosciences, Insightec, Inc. DNAtrix Inc, Immunomic Therapeutics, Seneca Therapeutics, GSK, and Voyager Therapeutics and has equity interest in DNAtrix, Immunomic Therapeutics, and Seneca Therapeutics; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx. Ziopharm Oncology, Cerebral Therapeutics, Genenta. Merck, Janssen, Karcinolysis, Shanghai Biotech, and Sangamo Therapeutics. He has received research support from NIH, US Department of Defense, American Brain Tumor Association, National Brain Tumor Society, Alliance for Cancer Gene Therapy, Neurosurgical Research Education Foundation, Advantagene, NewLink Genetics, and Amgen. He also is a named inventor on patents related to oncolytic HSV1 and noncoding RNAs.",
year = "2022",
month = feb,
doi = "10.1016/j.hoc.2021.08.003",
language = "English (US)",
volume = "36",
pages = "63--75",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders",
number = "1",
}